Erosion of Dosage Compensation Impacts Human iPSC Disease Modeling
Erosion of Dosage Compensation Impacts Human iPSC Disease Modeling.pdf (2.736Mb)
Access StatusFull text of the requested work is not available in DASH at this time ("dark deposit"). For more information on dark deposits, see our FAQ.
de Boer, A. Sophie
MetadataShow full item record
CitationMekhoubad, Shila, Christoph Bock, A. Sophie de Boer, Evangelos Kiskinis, Alexander Meissner, and Kevin Carl Eggan. 2012. “Erosion of Dosage Compensation Impacts Human iPSC Disease Modeling.” Cell Stem Cell 10 (5): 595–609.
AbstractAlthough distinct human induced pluripotent stem cell (hiPSC) lines can display considerable epigenetic variation, it has been unclear whether such variability impacts their utility for disease modeling. Here, we show that although low-passage female hiPSCs retain the inactive X chromosome of the somatic cell they are derived from, over time in culture they undergo an “erosion” of X chromosome inactivation (XCI). This erosion of XCI is characterized by loss of XIST expression and foci of H3-K27-trimethylation, as well as transcriptional derepression of genes on the inactive X that cannot be reversed by either differentiation or further reprogramming. We specifically demonstrate that erosion of XCI has a significant impact on the use of female hiPSCs for modeling Lesch-Nyhan syndrome. However, our finding that most genes subject to XCI are derepressed by this erosion of XCI suggests that it should be a significant consideration when selecting hiPSC lines for modeling any disease.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:33010380
- FAS Scholarly Articles